» Articles » PMID: 17669098

A Report Card to Grade Helicobacter Pylori Therapy

Overview
Journal Helicobacter
Specialty Microbiology
Date 2007 Aug 3
PMID 17669098
Citations 146
Authors
Affiliations
Soon will be listed here.
Abstract

Helicobacter pylori causes a serious bacterial infectious disease, and the expectations of therapy should reflect this fact. Increasing antibiotic resistance, especially to clarithromycin, has significantly undermined the effectiveness of legacy triple therapy consisting of a proton pump inhibitor, clarithromycin, and amoxicillin. Current cure rates are consistently below 80% intention-to-treat, the accepted threshold separating acceptable from unacceptable treatment results. Grading clinical studies into effectiveness categories using prespecified criteria would allow clinicians to objectively identify and compare regimens. We offer a therapy report card similar to that used to grade the performance of school children. The intention-to-treat cure rate categories are: F or unacceptable ( 80%), D or poor (81-84%), C or fair (85-89%), B or good (90-95%), and A or excellent (95-100%). The category of "excellent" is based on the cure rates expected with other prevalent bacterial infectious diseases. We propose that only therapies that score "excellent" (grade = A) should be prescribed. Regimens scoring as B or "good" can be used if "excellent" results are not obtainable. In most regions legacy triple therapy should be abandoned as unacceptable. Quadruple therapy and sequential therapy are reasonable alternatives for initial therapy.

Citing Articles

Inhibition, Gastritis Attenuation, and Gut Microbiota Protection in C57BL/6 Mice by NCUH062003.

Li J, Xu X, Yang S, Liu K, Wu M, Xie M Microorganisms. 2025; 12(12.

PMID: 39770724 PMC: 11678540. DOI: 10.3390/microorganisms12122521.


The use of real-world evidence to generate cost analysis of antibiotic susceptibility testing (AST) in patients with treatment failure in Thailand: A large population-based study.

Aumpan N, Gamnarai P, Wongcha-Um A, Miftahussurur M, Yamaoka Y, Vilaichone R Heliyon. 2024; 10(21):e39189.

PMID: 39512463 PMC: 11539252. DOI: 10.1016/j.heliyon.2024.e39189.


Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for infection between 2013 and 2021: results from the European registry on management (Hp-EuReg).

Olmedo L, Calvet X, Gene E, Bordin D, Voynovan I, Castro-Fernandez M Gut. 2024; 74(1):15-25.

PMID: 39461739 PMC: 11671959. DOI: 10.1136/gutjnl-2024-332804.


Vonoprazan a novel potassium competitive acid blocker; another leap forward.

Elsabaawy M, Shaban A, Al-Arab A, Elbahr O, Edrees A, Afify S Prz Gastroenterol. 2024; 19(2):135-142.

PMID: 38939071 PMC: 11200074. DOI: 10.5114/pg.2024.139426.


Amoxicillin, gemifloxacin and rabeprazole, as first-line Helicobacter pylori therapy in clinical practice: A pilot study.

Kilic G, Kilic G, Ozkahraman A, Konur S, Dertli R, Kayar Y Medicine (Baltimore). 2024; 103(18):e38012.

PMID: 38701320 PMC: 11062647. DOI: 10.1097/MD.0000000000038012.